Excretion of prostacyclin and thromboxane metabolites before, during, and after pregnancy-induced hypertension.
The aim of the present study was to assess whether changes in prostacyclin (PGI2) and thromboxane (TXA2) generation precede the manifestation of pregnancy-induced hypertension (PH). The metabolites 6-oxo-PGF1 alpha and TXB2 were measured in the urine of 69 randomly selected pregnant women from 16-20 weeks of gestation (wg) until delivery and more than 6 weeks postpartum. Between 16-20 and 21-24 wg 6-oxo-PGF1 alpha excretion did not change in patients who later developed PIH (n = 6) but increased significantly in the control group (n = 63). In contrast, a marked rise in TXB2 excretion was found in the PIH group but not in controls. Thereafter significant differences between both groups persisted from 25 wg until delivery. The 6-oxo-PGF1 alpha/TXB2 ratio was below the 10th percentile from 21-24 wg until delivery in patients with developing PIH. The excretion of both metabolites was substantially lower in the non-pregnant state without any difference between patient groups. These results show an altered urinary excretion of both 6-oxo-PGF1 alpha and TXB2 preceding the onset of the disease. A pathophysiological role of PGI2 deficiency and increased TXA2 formation in PIH appears substantiated.
Klockenbusch
W
W
Frauenklinik, Heinrich-Heine-Universität, Düsseldorf, Germany.
Somville
T
T
Hafner
D
D
Strobach
H
H
Schrör
K
K
D015121:6-Ketoprostaglandin F1 alpha / Q000652:urine*; D000328:Adult; D005260:Female; D006801:Humans; D049590:Postpartum Period; D011225:Pre-Eclampsia / Q000652:urine*; D011247:Pregnancy; D011446:Prospective Studies; D013929:Thromboxane B2 / Q000652:urine*
D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha